A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Clinical trial NCT05147493 · UNKNOWN

Trial details

NCT number: NCT05147493
Sponsor: Hellenic Society of Hematology
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma Renal Impairment Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Paraproteinemias Blood Protein Disorders Hematologic Diseases

Start date: 2022-04-01
Primary completion: 2024-12-01
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.